RhumbLine Advisers
IMRX icon

RhumbLine Advisers’s Immuneering IMRX Stock Holding History

RhumbLine Advisers’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$329K Buy
+65,914
New +$333K ﹤0.01% 3011
2024
Q3 		– Sell
-3,386
Closed -$4.33K – 4261
2024
Q2 		$4.33K Sell
3,386
-17,546
-84% -$28.8K ﹤0.01% 4106
2024
Q1 		$60.5K Buy
20,932
+909
+5% +$5.09K ﹤0.01% 3584
2023
Q4 		$147K Buy
20,023
+217
+1% +$1.45K ﹤0.01% 3321
2023
Q3 		$152K Buy
19,806
+2,275
+13% +$20.9K ﹤0.01% 3302
2023
Q2 		$178K Buy
+17,531
New +$169K ﹤0.01% 3297
2022
Q2 		– Sell
-13,819
Closed -$89K – 3164
2022
Q1 		$89K Buy
+13,819
New +$133K ﹤0.01% 2907

Other funds holding IMRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
DA
DCF Advisers Greenwich, Connecticut $566M AUM 197.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

RhumbLine Advisers's IMRX Position: Q2 2026 in Review

RhumbLine Advisers opened a new position in Immuneering (IMRX) in Q2 2026: 65,914 shares worth $329K. The stake represents ﹤0.01% of the portfolio and ranks #3011 among its holdings. This is a return to the name: RhumbLine Advisers previously reported a position in IMRX as recently as Q2 2024.

RhumbLine Advisers first reported a position in IMRX in Q1 2022 and has held it in 7 quarters since. 111 funds tracked by Wall St. Rank hold IMRX as of Q2 2026.

  • RhumbLine Advisers held 65,914 shares of Immuneering worth $329K as of Q2 2026.
  • Immuneering was a new RhumbLine Advisers position in Q2 2026.
  • Immuneering made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #3011 holding.
  • RhumbLine Advisers first reported a position in Immuneering in Q1 2022 and has held it in 7 quarters since.
  • 111 funds tracked by Wall St. Rank held Immuneering as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.